MA27702A1 - Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation - Google Patents

Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation

Info

Publication number
MA27702A1
MA27702A1 MA28341A MA28341A MA27702A1 MA 27702 A1 MA27702 A1 MA 27702A1 MA 28341 A MA28341 A MA 28341A MA 28341 A MA28341 A MA 28341A MA 27702 A1 MA27702 A1 MA 27702A1
Authority
MA
Morocco
Prior art keywords
preparation
active ingredients
sterile aqueous
aqueous suspensions
inhalation
Prior art date
Application number
MA28341A
Other languages
English (en)
Inventor
Andrea Capocchi
Fausto Pivetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA27702A1 publication Critical patent/MA27702A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/02—Non-contaminated water, e.g. for industrial water supply
    • C02F2103/026—Treating water for medical or cosmetic purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation de suspensions aqueuses stériles constituées d'ingrédients actifs se présentant sous forme de particules cristallines micronisées, destinées à l'administration par inhalation. Cette invention porte plus particulièrement sur la préparation de suspensions aqueuses stériles à base d'ingrédients pharmaceutiques actifs se présentant sous forme d'hydrates cristallins.
MA28341A 2002-12-18 2005-06-16 Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation MA27702A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002674A ITMI20022674A1 (it) 2002-12-18 2002-12-18 Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.

Publications (1)

Publication Number Publication Date
MA27702A1 true MA27702A1 (fr) 2006-01-02

Family

ID=32587870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28341A MA27702A1 (fr) 2002-12-18 2005-06-16 Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation

Country Status (23)

Country Link
US (1) US8128909B2 (fr)
EP (1) EP1572153B1 (fr)
CN (1) CN100398095C (fr)
AT (1) ATE544445T1 (fr)
AU (1) AU2003294879A1 (fr)
BR (1) BRPI0316908B8 (fr)
CA (1) CA2510263C (fr)
DK (1) DK1572153T3 (fr)
EA (1) EA008122B1 (fr)
ES (1) ES2379349T3 (fr)
HK (1) HK1088217A1 (fr)
HR (1) HRP20050546B1 (fr)
IT (1) ITMI20022674A1 (fr)
MA (1) MA27702A1 (fr)
ME (2) MEP35208A (fr)
MX (1) MXPA05006441A (fr)
PL (1) PL213704B1 (fr)
PT (1) PT1572153E (fr)
RS (1) RS52151B (fr)
SI (1) SI1572153T1 (fr)
UA (1) UA87655C2 (fr)
WO (1) WO2004054545A1 (fr)
ZA (1) ZA200504897B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2006040598A2 (fr) * 2004-10-12 2006-04-20 Generics (Uk) Limited Preparation de formulations d'aerosol en suspension
EP1949891A1 (fr) * 2004-10-12 2008-07-30 Generics (UK) Limited Procédé pour la préparation de formules à suspension pour aérosol, caractérisé en ce que les particles soient formées par précipitation à l'intérieur d'un récipient
EP1683514B1 (fr) 2005-01-20 2012-05-23 Eratech S.r.l. Procédé de préparation de suspensions concentrées et une trousse de ceci
EP1782797A1 (fr) * 2005-11-02 2007-05-09 Pharmatex Italia Srl Procédé de préparation de composés pharmaceutiques stériles pulvérulents
EP2146695A4 (fr) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd Compositions pharmaceutiques
BRPI0815382A2 (pt) * 2007-07-31 2015-02-10 Otsuka Pharma Co Ltd Métodos para a produção de suspensão de aripiprazol e formulação de secagem por congelamento
AU2008334547B2 (en) * 2007-12-13 2011-06-30 Novartis Ag Organic compounds
GB0806873D0 (en) * 2008-04-16 2008-05-21 Breath Ltd Steroid nebuliser formulation
CN101618019B (zh) * 2008-07-01 2011-08-03 上海通用药业股份有限公司 一种醋酸曲安奈德微粒及其制备方法和药物组合物
WO2012095439A1 (fr) 2011-01-12 2012-07-19 Intervet International B.V. Utilisation d'échange de milieu liquide par filtration à contrecourant dans la préparation de suspensions de médicament
BR112013027391A2 (pt) 2011-05-03 2017-01-17 Chiesi Farmaceutic S P A formulação farmacêutica, frasco e kit
JP4954345B1 (ja) * 2011-07-06 2012-06-13 アピ株式会社 医薬品原薬の無菌化精製装置
DK3517541T3 (da) * 2012-05-08 2020-09-07 Nicox Ophthalmics Inc Polymorf form af fluticasonpropionat
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
ES2764495T3 (es) * 2015-10-09 2020-06-03 Bgh Procedimiento para cristalizar clatratos hidratos y procedimiento de purificación de un líquido acuoso usando los clatratos hidratos así cristalizados
WO2024180569A1 (fr) * 2023-03-01 2024-09-06 Ajaykumar Balraj Kanduri Suspension de nébulisation aqueuse synergique pour la gestion de troubles respiratoires infectieux et processus de préparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
AR018183A1 (es) * 1998-04-18 2001-10-31 Glaxo Group Ltd Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE60325459D1 (de) 2002-02-19 2009-02-05 Resolution Chemicals Ltd Auf lösungsmitteln basierende sterilisation von steroiden

Also Published As

Publication number Publication date
UA87655C2 (ru) 2009-08-10
ATE544445T1 (de) 2012-02-15
HRP20050546A2 (en) 2005-10-31
EP1572153A1 (fr) 2005-09-14
HK1088217A1 (en) 2006-11-03
HRP20050546B1 (hr) 2014-05-23
BR0316908A (pt) 2005-10-18
US20070140980A1 (en) 2007-06-21
DK1572153T3 (da) 2012-03-05
RS52151B (en) 2012-08-31
CA2510263A1 (fr) 2004-07-01
CN1735403A (zh) 2006-02-15
ITMI20022674A1 (it) 2004-06-19
ZA200504897B (en) 2006-09-27
WO2004054545A1 (fr) 2004-07-01
BRPI0316908B8 (pt) 2021-05-25
PT1572153E (pt) 2012-03-22
MXPA05006441A (es) 2005-09-08
AU2003294879A1 (en) 2004-07-09
CN100398095C (zh) 2008-07-02
EP1572153B1 (fr) 2012-02-08
CA2510263C (fr) 2012-07-03
SI1572153T1 (sl) 2012-05-31
ME01084B (me) 2011-05-10
RS72504A (en) 2006-10-27
US8128909B2 (en) 2012-03-06
PL213704B1 (pl) 2013-04-30
EA200500833A1 (ru) 2006-02-24
EA008122B1 (ru) 2007-04-27
MEP35208A (en) 2011-02-10
ES2379349T3 (es) 2012-04-25
BRPI0316908B1 (pt) 2016-01-26
PL377345A1 (pl) 2006-01-23

Similar Documents

Publication Publication Date Title
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
PL370111A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
EP1201239A4 (fr) Antagonistes d'amine cyclique ccr3
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
BR0208027A (pt) Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo
MY125099A (en) Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
WO2001047913A3 (fr) Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0102440D0 (sv) New compound
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BE2016C017I2 (fr)
AU2002358819A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
MXPA01007705A (es) Derivado de benzamida y medicamento que lo contiene.
IL163025A (en) Prucalopride - n - oxides, their preparation and pharmaceutical compositions comprising them